Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 16/2023

12.08.2023 | Research

Construction and validation of nomograms for predicting the prognosis of elderly patients with uterine serous carcinoma: a SEER-based study

verfasst von: Tingting Liu, He Zhang, Chao Han, Weimin Kong

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 16/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate the prognostic indicators, develop and verify nomograms for predicting overall survival (OS) and cancer-specific survival (CSS) in elderly patients with uterine serous carcinoma (USC).

Methods

Data of eligible USC patients aged ≥ 65 years from 2004 to 2015 in the Surveillance, Epidemiology and End Results (SEER) database were collected for retrospective analysis. X-tile software was used to assess the optimal cut-off values. Univariate and multivariate Cox regression analyses were performed to explore the prognostic factors. Nomograms were developed to predict the probability of 1-, 3- and 5-year OS and CSS. Concordance indexes (c-index), receiver operating characteristic analysis and calibration curves were used to evaluate the model. Decision curve analysis (DCA) was introduced to examine the clinical value of the models.

Results

Age, Federation International of Gynecology and Obstetrics stage, N stage, tumor size, number of lymph nodes resected, and adjuvant therapy were independent prognostic factors for OS and CSS. The C-indexes were 0.736 (OS), 0.754 (CSS) in the training set and 0.731 (OS), 0.759 (CSS) in the validation set. The area under the curve (AUCs) of OS and CSS for 1-, 3-, and 5-years all exceeded 0.75. The calibration plots for the probability of survival were in good agreement. As shown in DCA curves, the nomograms showed better discrimination power and higher net benefits than the 6th American Joint Committee on Cancer staging system.

Conclusions

The nomograms constructed based on prognostic risk factors could individually predict the prognosis of elderly USC patients and provide a reference for clinical decision-making.
Literatur
Zurück zum Zitat Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, Takehara K, Denys H, Nout RA, Lorusso D, Vaughan MM, Bini M, Takano M, Provencher D, Indini A, Sagae S, Wimberger P, Póka R, Segev Y, Kim SI, Candido Dos Reis FJ, Lopez S, Mariani A, Leitao MM Jr, Raspagliesi F, Panici PB, Di Donato V, Muzii L, Colombo N, Scambia G, Pignata S, Monk BJ (2021) Uterine serous carcinoma. Gynecol Oncol 162:226–234. https://doi.org/10.1016/j.ygyno.2021.04.029CrossRefPubMedPubMedCentral Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, Takehara K, Denys H, Nout RA, Lorusso D, Vaughan MM, Bini M, Takano M, Provencher D, Indini A, Sagae S, Wimberger P, Póka R, Segev Y, Kim SI, Candido Dos Reis FJ, Lopez S, Mariani A, Leitao MM Jr, Raspagliesi F, Panici PB, Di Donato V, Muzii L, Colombo N, Scambia G, Pignata S, Monk BJ (2021) Uterine serous carcinoma. Gynecol Oncol 162:226–234. https://​doi.​org/​10.​1016/​j.​ygyno.​2021.​04.​029CrossRefPubMedPubMedCentral
Zurück zum Zitat Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann J, Bosse T, Chargari C, Fagotti A, Fotopoulou C, Gonzalez Martin A, Lax S, Lorusso D, Marth C, Morice P, Nout RA, O’Donnell D, Querleu D, Raspollini MR, Sehouli J, Sturdza A, Taylor A, Westermann A, Wimberger P, Colombo N, Planchamp F, Creutzberg CL (2021) ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 31:12–39. https://doi.org/10.1136/ijgc-2020-002230CrossRefPubMed Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann J, Bosse T, Chargari C, Fagotti A, Fotopoulou C, Gonzalez Martin A, Lax S, Lorusso D, Marth C, Morice P, Nout RA, O’Donnell D, Querleu D, Raspollini MR, Sehouli J, Sturdza A, Taylor A, Westermann A, Wimberger P, Colombo N, Planchamp F, Creutzberg CL (2021) ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 31:12–39. https://​doi.​org/​10.​1136/​ijgc-2020-002230CrossRefPubMed
Zurück zum Zitat de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Damico R, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Gribaudo S, Provencher D, Hanzen C, Kruitwagen RF, Smit VTHBM, Singh N, Do V, Lissoni A, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL, PORTEC Study Group (2019) Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol 20:1273–1285. https://doi.org/10.1016/S1470-2045(19)30395-XCrossRefPubMedPubMedCentral de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Damico R, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Gribaudo S, Provencher D, Hanzen C, Kruitwagen RF, Smit VTHBM, Singh N, Do V, Lissoni A, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL, PORTEC Study Group (2019) Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol 20:1273–1285. https://​doi.​org/​10.​1016/​S1470-2045(19)30395-XCrossRefPubMedPubMedCentral
Zurück zum Zitat Ditto A, Leone Roberti Maggiore U, Lopez S, Martinelli F, Bogani G, Lo Vullo S, Brusadelli C, Paolini B, Ducceschi M, Mantiero M, Chiappa V, Signorelli M, Evangelista M, Mariani L, Raspagliesi F (2022) Uterine serous carcinoma: role of surgery, risk factors and oncologic outcomes. Experience of a tertiary center. Eur J Surg Oncol 48:268–274. https://doi.org/10.1016/j.ejso.2021.10.011CrossRefPubMed Ditto A, Leone Roberti Maggiore U, Lopez S, Martinelli F, Bogani G, Lo Vullo S, Brusadelli C, Paolini B, Ducceschi M, Mantiero M, Chiappa V, Signorelli M, Evangelista M, Mariani L, Raspagliesi F (2022) Uterine serous carcinoma: role of surgery, risk factors and oncologic outcomes. Experience of a tertiary center. Eur J Surg Oncol 48:268–274. https://​doi.​org/​10.​1016/​j.​ejso.​2021.​10.​011CrossRefPubMed
Zurück zum Zitat Hag-Yahia N, Gemer O, Eitan R, Raban O, Vaknin Z, Levy T, Leytes S, Lavie O, Ben-Arie A, Amit A, Namazov A, Volodarsky M, Ben-Shachar I, Atlas I, Bruchim I, Kadan Y, Helpman L (2021) Age is an independent predictor of outcome in endometrial cancer patients: an Israeli Gynecology Oncology Group cohort study. Acta Obstet Gynecol Scand 100:444–452. https://doi.org/10.1111/aogs.14015CrossRefPubMed Hag-Yahia N, Gemer O, Eitan R, Raban O, Vaknin Z, Levy T, Leytes S, Lavie O, Ben-Arie A, Amit A, Namazov A, Volodarsky M, Ben-Shachar I, Atlas I, Bruchim I, Kadan Y, Helpman L (2021) Age is an independent predictor of outcome in endometrial cancer patients: an Israeli Gynecology Oncology Group cohort study. Acta Obstet Gynecol Scand 100:444–452. https://​doi.​org/​10.​1111/​aogs.​14015CrossRefPubMed
Zurück zum Zitat Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, George S, Han E, Higgins S, Huh WK, Lurain JR III, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Wyse E, Yashar CM, McMillian NR, Scavone JL (2018) Uterine neoplasms, version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 16:170–199. https://doi.org/10.6004/jnccn.2018.0006CrossRefPubMed Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, George S, Han E, Higgins S, Huh WK, Lurain JR III, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Wyse E, Yashar CM, McMillian NR, Scavone JL (2018) Uterine neoplasms, version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 16:170–199. https://​doi.​org/​10.​6004/​jnccn.​2018.​0006CrossRefPubMed
Zurück zum Zitat Lancellotta V, De Felice F, Vicenzi L, Antonacci A, Cerboneschi V, Costantini S, di Cristino D, Tagliaferri L, Cerrotta A, Vavassori A, Gribaudo S, Colombo A, Lucà F, Barbara R, Mangoni M, Marampon F, Musio D, Bellati F, Torcia F, Tombolini V, Osti MF, De Sanctis V (2020) The role of vaginal brachytherapy in stage I endometrial serous cancer: a systematic review. J Contemp Brachytherapy 12:61–66. https://doi.org/10.5114/jcb.2020.92698CrossRefPubMedPubMedCentral Lancellotta V, De Felice F, Vicenzi L, Antonacci A, Cerboneschi V, Costantini S, di Cristino D, Tagliaferri L, Cerrotta A, Vavassori A, Gribaudo S, Colombo A, Lucà F, Barbara R, Mangoni M, Marampon F, Musio D, Bellati F, Torcia F, Tombolini V, Osti MF, De Sanctis V (2020) The role of vaginal brachytherapy in stage I endometrial serous cancer: a systematic review. J Contemp Brachytherapy 12:61–66. https://​doi.​org/​10.​5114/​jcb.​2020.​92698CrossRefPubMedPubMedCentral
Zurück zum Zitat Matei D, Filiaci V, Randall ME, Mutch D, Steinhoff MM, DiSilvestro PA, Moxley KM, Kim YM, Powell MA, O’Malley DM, Spirtos NM, Small W Jr, Tewari KS, Richards WE, Nakayama J, Matulonis UA, Huang HQ, Miller DS (2019) Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. N Engl J Med 380:2317–2326. https://doi.org/10.1056/NEJMoa1813181CrossRefPubMedPubMedCentral Matei D, Filiaci V, Randall ME, Mutch D, Steinhoff MM, DiSilvestro PA, Moxley KM, Kim YM, Powell MA, O’Malley DM, Spirtos NM, Small W Jr, Tewari KS, Richards WE, Nakayama J, Matulonis UA, Huang HQ, Miller DS (2019) Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. N Engl J Med 380:2317–2326. https://​doi.​org/​10.​1056/​NEJMoa1813181CrossRefPubMedPubMedCentral
Zurück zum Zitat Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, Wolk A, Wentzensen N, Weiss NS, Webb PM, van den Brandt PA, van de Vijver K, Thompson PJ, Australian National Endometrial Cancer Study Group, Strom BL, Spurdle AB, Soslow RA, Shu XO, Schairer C, Sacerdote C, Rohan TE, Robien K, Risch HA, Ricceri F, Rebbeck TR, Rastogi R, Prescott J, Polidoro S, Park Y, Olson SH, Moysich KB, Miller AB, McCullough ML, Matsuno RK, Magliocco AM, Lurie G, Lu L, Lissowska J, Liang X, Lacey JV Jr, Kolonel LN, Henderson BE, Hankinson SE, Håkansson N, Goodman MT, Gaudet MM, Garcia-Closas M, Friedenreich CM, Freudenheim JL, Doherty J, De Vivo I, Courneya KS, Cook LS, Chen C, Cerhan JR, Cai H, Brinton LA, Bernstein L, Anderson KE, Anton-Culver H, Schouten LJ, Horn-Ross PL (2013) Type I and II endometrial cancers: have they different risk factors? J Clin Oncol 31:2607–2618. https://doi.org/10.1200/JCO.2012.48.2596CrossRefPubMedPubMedCentral Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, Wolk A, Wentzensen N, Weiss NS, Webb PM, van den Brandt PA, van de Vijver K, Thompson PJ, Australian National Endometrial Cancer Study Group, Strom BL, Spurdle AB, Soslow RA, Shu XO, Schairer C, Sacerdote C, Rohan TE, Robien K, Risch HA, Ricceri F, Rebbeck TR, Rastogi R, Prescott J, Polidoro S, Park Y, Olson SH, Moysich KB, Miller AB, McCullough ML, Matsuno RK, Magliocco AM, Lurie G, Lu L, Lissowska J, Liang X, Lacey JV Jr, Kolonel LN, Henderson BE, Hankinson SE, Håkansson N, Goodman MT, Gaudet MM, Garcia-Closas M, Friedenreich CM, Freudenheim JL, Doherty J, De Vivo I, Courneya KS, Cook LS, Chen C, Cerhan JR, Cai H, Brinton LA, Bernstein L, Anderson KE, Anton-Culver H, Schouten LJ, Horn-Ross PL (2013) Type I and II endometrial cancers: have they different risk factors? J Clin Oncol 31:2607–2618. https://​doi.​org/​10.​1200/​JCO.​2012.​48.​2596CrossRefPubMedPubMedCentral
Metadaten
Titel
Construction and validation of nomograms for predicting the prognosis of elderly patients with uterine serous carcinoma: a SEER-based study
verfasst von
Tingting Liu
He Zhang
Chao Han
Weimin Kong
Publikationsdatum
12.08.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 16/2023
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-023-05174-3

Weitere Artikel der Ausgabe 16/2023

Journal of Cancer Research and Clinical Oncology 16/2023 Zur Ausgabe

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.